U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry RACEMIC
Molecular Formula C34H38N3O7P
Molecular Weight 631.6552
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of EFONIDIPINE

SMILES

CC1=C(C(C2=CC=CC(=C2)[N+]([O-])=O)C(=C(C)N1)P3(=O)OCC(C)(C)CO3)C(=O)OCCN(CC4=CC=CC=C4)C5=CC=CC=C5

InChI

InChIKey=NSVFSAJIGAJDMR-UHFFFAOYSA-N
InChI=1S/C34H38N3O7P/c1-24-30(33(38)42-19-18-36(28-15-9-6-10-16-28)21-26-12-7-5-8-13-26)31(27-14-11-17-29(20-27)37(39)40)32(25(2)35-24)45(41)43-22-34(3,4)23-44-45/h5-17,20,31,35H,18-19,21-23H2,1-4H3

HIDE SMILES / InChI

Description

Efonidipine is a 1,4-dihydropyridine derivative for the treatment of hypertension and angina. Efonidipine exerts its antihypertensive and antianginal effects through blocking L- and T-type calcium channels.

Originator

Approval Year

Unknown
149124
Targets

Targets

Primary TargetPharmacologyConditionPotency
Blocker
555
 13.0 nM [IC50]
Blocker
555
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Approved
8583
LANDEL

Approved Use

Unknown
Primary
Approved
8583
LANDEL

Approved Use

Unknown
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
1.7 ng/mL
OTHER GOV'T
https://www.info.pmda.go.jp/go/interview/3/380077_2149034F1020_3_1F.pdf#page=22
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
EFONIDIPINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
11.7 ng/mL
OTHER GOV'T
https://www.info.pmda.go.jp/go/interview/3/380077_2149034F1020_3_1F.pdf#page=22
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
EFONIDIPINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
17.9 ng/mL
OTHER GOV'T
https://www.info.pmda.go.jp/go/interview/3/380077_2149034F1020_3_1F.pdf#page=22
40 mg single, oral
dose: 40 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
EFONIDIPINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
10.8 ng/mL
OTHER GOV'T
https://www.info.pmda.go.jp/go/interview/3/380077_2149034F1020_3_1F.pdf#page=23
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
EFONIDIPINE plasma
Homo sapiens
population: UNKNOWN
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
12.9 ng/mL
OTHER GOV'T
https://www.info.pmda.go.jp/go/interview/3/380077_2149034F1020_3_1F.pdf#page=23
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
EFONIDIPINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
19.7 ng/mL
OTHER GOV'T
https://www.info.pmda.go.jp/go/interview/3/380077_2149034F1020_3_1F.pdf#page=23
30 mg single, oral
dose: 30 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
EFONIDIPINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
26.1 ng/mL
OTHER GOV'T
https://www.info.pmda.go.jp/go/interview/3/380077_2149034F1020_3_1F.pdf#page=23
30 mg single, oral
dose: 30 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
EFONIDIPINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
4.1 ng × h/mL
OTHER GOV'T
https://www.info.pmda.go.jp/go/interview/3/380077_2149034F1020_3_1F.pdf#page=22
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
EFONIDIPINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
25.4 ng × h/mL
OTHER GOV'T
https://www.info.pmda.go.jp/go/interview/3/380077_2149034F1020_3_1F.pdf#page=22
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
EFONIDIPINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
57.6 ng × h/mL
OTHER GOV'T
https://www.info.pmda.go.jp/go/interview/3/380077_2149034F1020_3_1F.pdf#page=22
40 mg single, oral
dose: 40 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
EFONIDIPINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
34.7 ng × h/mL
OTHER GOV'T
https://www.info.pmda.go.jp/go/interview/3/380077_2149034F1020_3_1F.pdf#page=23
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
EFONIDIPINE plasma
Homo sapiens
population: UNKNOWN
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
31.5 ng × h/mL
OTHER GOV'T
https://www.info.pmda.go.jp/go/interview/3/380077_2149034F1020_3_1F.pdf#page=23
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
EFONIDIPINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
61.7 ng × h/mL
OTHER GOV'T
https://www.info.pmda.go.jp/go/interview/3/380077_2149034F1020_3_1F.pdf#page=23
30 mg single, oral
dose: 30 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
EFONIDIPINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
68.8 ng × h/mL
OTHER GOV'T
https://www.info.pmda.go.jp/go/interview/3/380077_2149034F1020_3_1F.pdf#page=23
30 mg single, oral
dose: 30 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
EFONIDIPINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
2.9 h
OTHER GOV'T
https://www.info.pmda.go.jp/go/interview/3/380077_2149034F1020_3_1F.pdf#page=22
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
EFONIDIPINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
1.4 h
OTHER GOV'T
https://www.info.pmda.go.jp/go/interview/3/380077_2149034F1020_3_1F.pdf#page=22
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
EFONIDIPINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
2.2 h
OTHER GOV'T
https://www.info.pmda.go.jp/go/interview/3/380077_2149034F1020_3_1F.pdf#page=22
40 mg single, oral
dose: 40 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
EFONIDIPINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
2 h
OTHER GOV'T
https://www.info.pmda.go.jp/go/interview/3/380077_2149034F1020_3_1F.pdf#page=23
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
EFONIDIPINE plasma
Homo sapiens
population: UNKNOWN
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
2.1 h
OTHER GOV'T
https://www.info.pmda.go.jp/go/interview/3/380077_2149034F1020_3_1F.pdf#page=23
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
EFONIDIPINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
1.8 h
OTHER GOV'T
https://www.info.pmda.go.jp/go/interview/3/380077_2149034F1020_3_1F.pdf#page=23
30 mg single, oral
dose: 30 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
EFONIDIPINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
1.7 h
OTHER GOV'T
https://www.info.pmda.go.jp/go/interview/3/380077_2149034F1020_3_1F.pdf#page=23
30 mg single, oral
dose: 30 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
EFONIDIPINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
0.2%
DRUG LABEL
https://www.info.pmda.go.jp/go/interview/3/380077_2149034F1020_3_1F.pdf#page=25
EFONIDIPINE serum
Homo sapiens
Doses

Doses

DosePopulationAdverse events​
40 mg 1 times / day multiple, oral
Recommended
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/24944418/
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/24944418/
Sources:
https://pubmed.ncbi.nlm.nih.gov/24944418/
PubMed

PubMed

TitleDatePubMed
Efonidipine hydrochloride: a dual blocker of L- and T-type ca(2+) channels.
2002 Winter

Sample Use Guides

In Vivo Use Guide
40 mg once daily for 12 weeks
Route of Administration: Oral
In Vitro Use Guide
Effects of efonidipine on isolated myocardial and aortic preparations was studied. The drug produced concentration-dependent negative chronotropic effects on isolated guinea-pig atrial preparations.The potency was 3.08 x 10(-8)M (EC30).
Name Type Language
(±)-EFONIDIPINE
Preferred Name English
EFONIDIPINE
INN   MI   WHO-DD  
INN  
Official Name English
Efonidipine [WHO-DD]
Common Name English
efonidipine [INN]
Common Name English
3-PYRIDINECARBOXYLIC ACID, 5-(5,5-DIMETHYL-2-OXIDO-1,3,2-DIOXAPHOSPHORINAN-2-YL)-1,4-DIHYDRO-2,6-DIMETHYL-4-(3-NITROPHENYL)-, 2-(PHENYL(PHENYLMETHYL)AMINO)ETHYL ESTER
Systematic Name English
EFONIDIPINE [MI]
Common Name English
2-(N-BENZYLANILINO)ETHYL (±)-1,4-DIHYDRO-2,6-DIMETHYL-4-(M-NITROPHENYL)-5-PHOSPHONONICOTINATE, CYCLIC 2,2-DIMETHYLTRIMETHYLENE ESTER
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C333
Created by admin on Mon Mar 31 18:30:56 GMT 2025 , Edited by admin on Mon Mar 31 18:30:56 GMT 2025
Code System Code Type Description
EPA CompTox
DTXSID9043988
Created by admin on Mon Mar 31 18:30:56 GMT 2025 , Edited by admin on Mon Mar 31 18:30:56 GMT 2025
PRIMARY
EVMPD
SUB06471MIG
Created by admin on Mon Mar 31 18:30:56 GMT 2025 , Edited by admin on Mon Mar 31 18:30:56 GMT 2025
PRIMARY
MERCK INDEX
m4841
Created by admin on Mon Mar 31 18:30:56 GMT 2025 , Edited by admin on Mon Mar 31 18:30:56 GMT 2025
PRIMARY Merck Index
CHEBI
135859
Created by admin on Mon Mar 31 18:30:56 GMT 2025 , Edited by admin on Mon Mar 31 18:30:56 GMT 2025
PRIMARY
NCI_THESAURUS
C73026
Created by admin on Mon Mar 31 18:30:56 GMT 2025 , Edited by admin on Mon Mar 31 18:30:56 GMT 2025
PRIMARY
PUBCHEM
119171
Created by admin on Mon Mar 31 18:30:56 GMT 2025 , Edited by admin on Mon Mar 31 18:30:56 GMT 2025
PRIMARY
SMS_ID
100000080517
Created by admin on Mon Mar 31 18:30:56 GMT 2025 , Edited by admin on Mon Mar 31 18:30:56 GMT 2025
PRIMARY
WIKIPEDIA
EFONIDIPINE
Created by admin on Mon Mar 31 18:30:56 GMT 2025 , Edited by admin on Mon Mar 31 18:30:56 GMT 2025
PRIMARY
DRUG BANK
DB09235
Created by admin on Mon Mar 31 18:30:56 GMT 2025 , Edited by admin on Mon Mar 31 18:30:56 GMT 2025
PRIMARY
CAS
111011-63-3
Created by admin on Mon Mar 31 18:30:56 GMT 2025 , Edited by admin on Mon Mar 31 18:30:56 GMT 2025
PRIMARY
FDA UNII
40ZTP2T37Q
Created by admin on Mon Mar 31 18:30:56 GMT 2025 , Edited by admin on Mon Mar 31 18:30:56 GMT 2025
PRIMARY
DRUG CENTRAL
992
Created by admin on Mon Mar 31 18:30:56 GMT 2025 , Edited by admin on Mon Mar 31 18:30:56 GMT 2025
PRIMARY
INN
6852
Created by admin on Mon Mar 31 18:30:56 GMT 2025 , Edited by admin on Mon Mar 31 18:30:56 GMT 2025
PRIMARY
ChEMBL
CHEMBL2074922
Created by admin on Mon Mar 31 18:30:56 GMT 2025 , Edited by admin on Mon Mar 31 18:30:56 GMT 2025
PRIMARY
MESH
C066425
Created by admin on Mon Mar 31 18:30:56 GMT 2025 , Edited by admin on Mon Mar 31 18:30:56 GMT 2025
PRIMARY
ACTIVE MOIETY
Structure of EFONIDIPINE
SALT/SOLVATE (PARENT)
Structure of EFONIDIPINE HYDROCHLORIDE
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966